Canopy Growth's Narrowest-Ever EBITDA Loss Masks a Share Price Stuck in the Doldrums

Canopy Growth posts record-low EBITDA loss but shares slip 3.4% below 50-day MA; EU-GMP renewal and September shareholder meeting in focus.

The gap between Canopy Growth's operational trajectory and its market valuation has rarely been wider. The Canadian cannabis producer just posted its smallest quarterly EBITDA loss on record, yet the stock continues to drift lower, leaving investors to puzzle over which signal carries more weight.

That tension was on full display Wednesday, when shares slipped 3.4 percent to fall back below the 50-day moving average of 0.8399 euros, a level the stock had only recently reclaimed. With no obvious news catalyst behind the pullback, market watchers pointed to persistent selling pressure that appears to lack a fundamental trigger.

A Quarter of Firsts Under New Leadership

The numbers themselves tell a story of steady, if incremental, progress. For the first quarter of fiscal 2027, which ended in June, Canopy grew net revenue 13 percent to 81.2 million Canadian dollars. It marked the first quarter under CEO Mongeau in which every business segment contributed to growth.

The adjusted EBITDA loss narrowed to 3.2 million Canadian dollars — the smallest shortfall in the company's history and a sign that cost discipline is beginning to take hold. Still, the bottom line remained in the red, with a net loss of 14.6 million Canadian dollars, underscoring just how arduous the path to profitability remains in Canada's cannabis sector.

The standout performer was Storz & Bickel, the vaporizer division, which saw revenue surge 45 percent in a single quarter — evidence that the hardware business is currently providing more momentum than the core cannabis operation. International cannabis sales also advanced 10 percent, and management reaffirmed its target of achieving positive adjusted EBITDA within the current fiscal year.

The European Anchor

Part of that international optimism rests on regulatory foundations that many North American rivals lack. In mid-August, Canopy confirmed the renewal of its EU-GMP certification for the Kincardine, Ontario facility, issued by the Regierungspräsidium Tübingen. The designation is essential for continuing to supply Canadian-grown medical cannabis to European markets.

Kincardine, together with the company's second facility in Sankt Leon-Rot, Germany, forms the backbone of a supply chain that differentiates Canopy from competitors who have not pursued such European standards. For a sector increasingly focused on regulatory reliability over pure market expansion, that positioning could prove decisive.

A September Shareholder Meeting With Teeth

Investors are now looking ahead to the annual and extraordinary general meeting scheduled for September 25, to be held via audio webcast at 1:00 p.m. Eastern Time. Beyond the routine items — board elections and the appointment of MNP LLP as auditor — the agenda includes a proposal for a share consolidation.

Management has urged shareholders to vote early to ensure the quorum required by Nasdaq is reached, avoiding the costs associated with a potential adjournment. The reverse-split proposal carries particular weight given the stock's extended slide.

Insider Activity: Noise, Not Signal

A recent director transaction, while small, offers a window into the broader investor psychology surrounding the stock. Director Theresa Yanofsky sold 10,373 shares on Monday at 0.93 Canadian dollars each, a modest amount against a market capitalization of 429.62 million euros. The sale, disclosed in a Form 4 filing with the U.S. securities regulator, was conducted to satisfy tax obligations tied to restricted stock units granted in June 2025. Yanofsky retains 53,145 shares directly — a routine administrative move rather than a vote of no confidence.

Sector Consolidation Heats Up

The broader industry backdrop is shifting. Curaleaf Holdings launched a formal takeover bid for Aurora Cannabis in mid-August, valuing the Canadian rival at roughly 260 million US dollars and offering shareholders a 45 percent premium over the 30-day average price. While the bid has no direct implications for Canopy, it underscores a consolidation phase in the North American cannabis industry in which scale and capital strength increasingly determine competitive survival.

The Valuation Conundrum

The stock's recent performance captures the market's ambivalence. After gaining 11 percent over the past 30 days, shares closed at 0.9010 euros — a modest recovery that looks far less impressive against the 52-week high of 2.00 euros reached in December. At 0.8700 euros, the stock trades roughly 56 percent below that peak, a persistent pattern in which operational improvements have repeatedly failed to translate into sustained share price gains.

The real question facing Canopy investors is whether one strong quarter can become a series. The operational progress is genuine — Storz & Bickel is delivering, international expansion is bearing fruit, and the European regulatory base is secure. But the market has extended credit to Canopy before without a lasting rally following. Whether this time proves different may ultimately depend on the company's ability to string together multiple quarters of execution, turning a promising snapshot into a sustained trajectory.